Gutierrez-Merino Carlos
Instituto de Biomarcadores de Patologías Moleculares, Universidad de Extremadura, 06006 Badajoz, Spain.
Int J Mol Sci. 2023 Sep 8;24(18):13846. doi: 10.3390/ijms241813846.
Amyloid β (Aβ) oligomers have been linked to Alzheimer's disease (AD) pathogenesis and are the main neurotoxic forms of Aβ. This review focuses on the following: (i) the Aβ(1-42):calmodulin interface as a model for the design of antagonist Aβ peptides and its limitations; (ii) proteolytic degradation as the major source of highly hydrophobic peptides in brain cells; and (iii) brain peptides that have been experimentally demonstrated to bind to Aβ monomers or oligomers, Aβ fibrils, or Aβ plaques. It is highlighted that the hydrophobic amino acid residues of the COOH-terminal segment of Aβ(1-42) play a key role in its interaction with intracellular protein partners linked to its neurotoxicity. The major source of highly hydrophobic endogenous peptides of 8-10 amino acids in neurons is the proteasome activity. Many canonical antigen peptides bound to the major histocompatibility complex class 1 are of this type. These highly hydrophobic peptides bind to Aβ and are likely to be efficient antagonists of the binding of Aβ monomers/oligomers concentrations in the nanomolar range with intracellular proteins. Also, their complexation with Aβ will protect them against endopeptidases, suggesting a putative chaperon-like physiological function for Aβ that has been overlooked until now. Remarkably, the hydrophobic amino acid residues of Aβ responsible for the binding of several neuropeptides partially overlap with those playing a key role in its interaction with intracellular protein partners that mediates its neurotoxicity. Therefore, these latter neuropeptides are also potential candidates to antagonize Aβ peptides binding to target proteins. In conclusion, the analysis performed in this review points out that hydrophobic endogenous brain neuropeptides could be valuable biomarkers to evaluate the risk of the onset of sporadic AD, as well as for the prognosis of AD.
淀粉样β(Aβ)寡聚体与阿尔茨海默病(AD)的发病机制有关,是Aβ的主要神经毒性形式。本综述聚焦于以下几点:(i)Aβ(1-42):钙调蛋白界面作为拮抗剂Aβ肽设计的模型及其局限性;(ii)蛋白水解降解作为脑细胞中高度疏水肽的主要来源;(iii)经实验证明能与Aβ单体或寡聚体、Aβ纤维或Aβ斑块结合的脑肽。需要强调的是,Aβ(1-42)羧基末端片段的疏水氨基酸残基在其与与其神经毒性相关的细胞内蛋白伴侣的相互作用中起关键作用。神经元中8 - 10个氨基酸的高度疏水内源性肽的主要来源是蛋白酶体活性。许多与主要组织相容性复合体I类结合的经典抗原肽就是这种类型。这些高度疏水的肽与Aβ结合,可能是纳摩尔浓度范围内Aβ单体/寡聚体与细胞内蛋白结合的有效拮抗剂。此外,它们与Aβ的络合将保护它们免受内肽酶的作用,这表明Aβ具有一种至今被忽视的类似分子伴侣的假定生理功能。值得注意的是,负责几种神经肽结合的Aβ疏水氨基酸残基与在其与介导其神经毒性的细胞内蛋白伴侣相互作用中起关键作用的残基部分重叠。因此,这些后一种神经肽也是拮抗Aβ肽与靶蛋白结合的潜在候选物。总之,本综述所进行的分析指出,疏水性内源性脑神经肽可能是评估散发性AD发病风险以及AD预后的有价值的生物标志物。